Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
Pathogenesis and Current Treatment of Osteosarcoma: Perspectives for Future Therapies.
复制标题
骨肉瘤的发病机制和目前的治疗：未来治疗的前景。
DOI：
10.3390/jcm10061182
复制
发表时间：
2021-03-12
影响因子：
3.9
通讯作者：
Van Tine BA
中科院分区：
文献类型：
--
作者：
Rathore R;Van Tine BA
骨肉瘤是儿童和年轻人最常见的原发性恶性骨肿瘤。骨肉瘤的标准治疗使用阿霉素、顺铂和大剂量甲氨蝶呤，这一标准在40多年中没有改变。患者特异性治疗的发展需要深入了解肿瘤的独特遗传学和生物学。在这里，我们讨论了正常骨生物学在骨肉瘤形成中的作用，强调了驱动正常成骨细胞产生以及异常骨肉瘤发展的因素。然后我们描述骨肉瘤的病理和目前的护理标准。鉴于骨肉瘤肿瘤的复杂异质性，我们探索了包含一系列分子靶点的骨肉瘤新疗法的发展。这一致病机制的分析将为未来骨肉瘤的治疗研究提供有希望的途径。
Osteosarcoma is the most common primary malignant bone tumor in children and young adults. The standard-of-care curative treatment for osteosarcoma utilizes doxorubicin, cisplatin, and high-dose methotrexate, a standard that has not changed in more than 40 years. The development of patient-specific therapies requires an in-depth understanding of the unique genetics and biology of the tumor. Here, we discuss the role of normal bone biology in osteosarcomagenesis, highlighting the factors that drive normal osteoblast production, as well as abnormal osteosarcoma development. We then describe the pathology and current standard of care of osteosarcoma. Given the complex heterogeneity of osteosarcoma tumors, we explore the development of novel therapeutics for osteosarcoma that encompass a series of molecular targets. This analysis of pathogenic mechanisms will shed light on promising avenues for future therapeutic research in osteosarcoma.
登录
查看更多内容
DOI：
10.1200/jco.2014.60.0734
发表时间：
2015-07-10
期刊：
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
影响因子：
--
作者：
Bielack SS;Smeland S;Whelan JS;Marina N;Jovic G;Hook JM;Krailo MD;Gebhardt M;Pápai Z;Meyer J;Nadel H;Randall RL;Deffenbaugh C;Nagarajan R;Brennan B;Letson GD;Teot LA;Goorin A;Baumhoer D;Kager L;Werner M;Lau CC;Sundby Hall K;Gelderblom H;Meyers P;Gorlick R;Windhager R;Helmke K;Eriksson M;Hoogerbrugge PM;Schomberg P;Tunn PU;Kühne T;Jürgens H;van den Berg H;Böhling T;Picton S;Renard M;Reichardt P;Gerss J;Butterfass-Bahloul T;Morris C;Hogendoorn PC;Seddon B;Calaminus G;Michelagnoli M;Dhooge C;Sydes MR;Bernstein M;EURAMOS-1 investigators
通讯作者：
EURAMOS-1 investigators
影响因子：
8.8
作者：
Chen X;Bahrami A;Pappo A;Easton J;Dalton J;Hedlund E;Ellison D;Shurtleff S;Wu G;Wei L;Parker M;Rusch M;Nagahawatte P;Wu J;Mao S;Boggs K;Mulder H;Yergeau D;Lu C;Ding L;Edmonson M;Qu C;Wang J;Li Y;Navid F;Daw NC;Mardis ER;Wilson RK;Downing JR;Zhang J;Dyer MA;St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project
通讯作者：
St. Jude Children’s Research Hospital–Washington University Pediatric Cancer Genome Project
影响因子：
9.7
作者：
Amorim, Ricardo;Pinheiro, Celine;Baltazar, Fatima
通讯作者：
Baltazar, Fatima
DOI：
10.1056/nejmoa1200694
发表时间：
2012-06-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Brahmer JR;Tykodi SS;Chow LQ;Hwu WJ;Topalian SL;Hwu P;Drake CG;Camacho LH;Kauh J;Odunsi K;Pitot HC;Hamid O;Bhatia S;Martins R;Eaton K;Chen S;Salay TM;Alaparthy S;Grosso JF;Korman AJ;Parker SM;Agrawal S;Goldberg SM;Pardoll DM;Gupta A;Wigginton JM
通讯作者：
Wigginton JM
影响因子：
5.3
作者：
García-Castro J;Trigueros C;Madrenas J;Pérez-Simón JA;Rodriguez R;Menendez P
通讯作者：
Menendez P